DISCOVERY Asia - Crestor in Type IIa and IIb Hypercholesteremia

Phase 3 Completed 1362 enrolled AstraZeneca

RandomizedParallel-groupOpen-labelTreatment

Summary

This clinical trial is being performed to investigate the effect of 12 weeks treatment with rosuvastatin and atorvastatin in bringing subjects to their established EAS LDL-C target goal.

Timeline

Start: 2003-06
Primary completion: 2005-12
Completion: 2007-02

Outcome

Met primary endpoint

paper rosuvastatin group (n = 950) compared with the atorvastatin group (n = 471) (79.5 vs. 69.4%, respectively; p < 0.0001). PMID 18196620 ↗

Publications

Zhu JR, Tomlinson B, Ro YM, Sim KH, Lee YT, Sriratanasathavorn C. A randomised study comparing the efficacy and safety of rosuvastatin with atorvastatin for achieving lipid goals in clinical practice in Asian patients at high risk of cardiovascular disease (DISCOVERY-Asia study). Curr Med Res Opin. 2007 Dec;23(12):3055-68. doi: 10.1185/030079907x242809.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rosuvastatin	Small molecule	10 mg	—

Indications

No indication recorded.